Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February
There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media.
$IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month.
iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores.
The company generates a majority of its revenue from its retail segment.
The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19.
www.benzinga.com
twitter.com
Coronaviruses
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?
over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race.
Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech.
In fact, over 30% of Vaxart stock has been sold short.
Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use.
At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week.
Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart.
Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS).
Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat.
Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about.
With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate.
Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
Heat Biologics HTBX is working on the Covid-19 vaccineHeat Biologics HTBX is one of the lowest market cap companies (65.51M) working on the Covid-19 vaccine. It has a lot of room to grow from it`s peak in Oct 4th 2013 (139,90 usd)
The indiccators are also showing a strong buying power.
Heat Biologics Inc. HTBX has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines.
The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts.
When COVID-19 will be gone?This analysis represents the trend of the rate of change of confirmed COVID-19 cases.
The positive change in the confirmed cases is expected to be negative in the beginning of May, and then 90% of the cases should be recovered by mid-july.
Covid19 potential topping patternWhen charting Covid19 US Deaths over Confirmed cases, the Pandemic is beginning to show weakness. After weeks period of increasing infections, those who had become infected have either died or recovered. That ratio, if near, is a "Lower High" than the one set in Early March. If we begin to see a trend of "Lower highs, Lower Lows", the pandemic is being contained. This chart will show the end.
Short US marketUS cases climbed by 13,000 to 68,000 cases (stats from worldometer site) already and it seems like the rally 2 days ago just took a small turn downwards. I still think it will continue heading downwards till either vaccine is released or when the numbers are better controlled. Because looking at the growth rate, it doesn't look like its slowing down and many countries have started partial shutdowns and I think the impact on their economy will be huge but the real effect on the economy can only be seen at a later stage.
What if CURES EXIST?what a time to be alive
doctors worldwide have gone from slowly writing long confusing peer reviewed journals.....TO FIGHTING DAILY TO FIND A CURE.
WHERE DID ALL THE BILLIONS OF $ TO FIGHT DISEASE GO BEFORE?
WHY DID IT TAKE A NATIONAL CRISIS TO FIGHT THIS HARD?
sheep no more.
We will have a collapse againHello everyone, Flag is clear so let's get to other reason, We have fast and strong movement and after that a spiritless and long correction, as you can see correction wave wasn't able to breakup even fibo 38.2 that it shows the power of bears, and another reason is high speed of spreading coronaviruses in USA and Europe, so for this reasons I will wait fore Elliot 5th impulse wave.
Take market easy
Don't forget to tap on like if you like my work.
Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).
Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com
Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com
Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly.
Disclaimer: This is not financial advice. Just my own opinion based on research.
Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
